Expression of HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic proteins Survivin and Bcl-2 via the extracellular signal-related kinase (ERK) and phosphoinositide-3 kinase (PI3K) signalling pathways
© Siddiqa et al; licensee BioMed Central Ltd. 2008
Received: 03 October 2007
Accepted: 02 May 2008
Published: 02 May 2008
The oncoprotein HER-2 is over-expressed and/or has undergone gene amplification in between 20 to 30% of breast and ovarian cancers. HER-2 amplified breast cancer is associated with a poor prognosis and increased resistance to chemo- and hormonal therapy. Data supporting the transforming potential of HER-2 are irrefutable but the mechanism by which HER-2 contributes to this process is complex and a unified model of HER2-induced increased cell proliferation and survival has not emerged.
To understand the initial event(s) that take place by HER-2 over expression, we studied the effect of short term induction of HER-2 expression in the MCF7 breast cancer cell line.
We examined the modulation of apoptotic pathways by tetracycline-regulated HER-2 expression for 48 hrs in the MCF7 breast cancer cell line. Specific inhibitors were used to determine signalling pathways that are required for HER-2 induced up-regulation of survivin.
Tetracycline regulated short term over expression of HER-2 in the MCF7 cell line increased the antiapoptotic proteins Bcl-2 and survivin levels. Significant increase of extracellular signal-related kinase (ERK) activation but not AKT1, AKT2 and STAT3 was observed in HER-2 over-expressing MCF7 cells. Specific inhibitors of ERK, and phosphoinositide-3 kinase (PI3K), inhibited the HER-2 induced up-regulation of survivin. We did not observe a change in survivin and NF-κB promoter activity in HER-2 expressing MCF7 cells.
Our results indicate that short term over expression of HER-2 up regulates antiapoptotic proteins Bcl-2 and survivin in MCF7 cells. We determined that survivin is up-regulated via ERK activation and PI3K signalling. Additionally we show that survivin up-regulation is not at transcriptional level. These data provide insight into the mechanism(s) by which induction of HER-2 over expression up-regulates survivin and Bcl-2 and identifies new targets for therapy of breast cancer.
Impaired apoptosis is critical in cancer development and is a major barrier to effective treatment. Apoptosis is executed by intracellular cysteine proteases called caspases. Two pathways lead to the caspase activation – the extrinsic and intrinsic pathways. The extrinsic pathway is initiated by ligation of death receptors . The intrinsic pathway requires disruption of mitochondrial membranes and release of cytochrome C . Molecules and signalling events that regulate apoptosis affect disease progression and the efficacy of chemotherapy because most chemotherapy kills cancer cells by inducing apoptosis .
HER-2 is a key molecule in the regulation of apoptosis in breast cancer cells . Approximately 25–30 percent of breast cancers have amplification of the HER-2/neu gene or over express HER-2, which correlates with poor prognosis and resistance to therapy . The ERBB/HER family of proteins consists of four tyrosine kinase, membrane bound receptors (HER1-4) and more than 13 polypeptide extracellular ligands. HER-2 lacks the capacity to interact with ligand , whereas the kinase activity of HER3 is defective . Despite this lack of autonomous ability to respond to a ligand, both HER-2 and HER3 form hetrodimeric complexes with other HER receptors that are capable of generating potent cellular signals. HER-2 containing heterodimers have a higher affinity and a broader specificity for various ligands than the other dimer receptor complexes, owing to slower rates of ligand dissociation. Also, HER-2-containing heterodimers have a slower rate of endocytosis and a higher rate of recycling back to the cell surface. These features translate to potent mitogenic and anti-apoptotic signals [8, 9]. HER-2 signalling is mediated by several sequentially activated protein kinases, some of which (ERK, JNK, p38MAPK) belong to super family of mitogen activated protein kinases (MAPK) [10, 11]. Other components of the intracellular signalling cascade activated by the ERBB/HER family of receptors include PI3K dependent activation of AKT , apoptotic signaling through Bcl-2  and the inhibitor of apoptosis (IAP) families of proteins .
The Bcl-2 family plays a pivotal role in the regulation of the mitochondrial "intrinsic" pathway of apoptosis . The Bcl-2 family is subdivided into antiapoptotic members, including Bcl-2 and Bcl-XL, and proapoptotic members, including Bax and Bak [16, 17]. Overexpression of antiapoptotic molecules Bcl-2 and Bcl-XL blocks cytochrome C release in response to apoptotic stimuli.
Expression of survivin, an inhibitor-of-apoptosis protein (IAP) family members, is also associated with resistance to apoptosis . Survivin inhibits activation of caspase-9, which is required for the initiation of the intrinsic mitochondrial pathway of apoptosis .
In this study we examined the modulation of apoptotic pathways by tetracycline-regulated HER-2 expression in the MCF7 breast cancer cell line. Our results indicate that HER-2 up regulates antiapoptotic proteins Bcl-2 and survivin as reported previously [20, 21]. Using specific signalling inhibitors we determined that survivin is up-regulated via ERK activation and PI3K signalling. Additionally we show that survivin upregulation is not at transcriptional level. These data provide insight into the mechanism(s) by which HER-2 over expression protects breast cancer cells from apoptosis and identifies new targets for therapy of breast cancer.
The human breast cancer cell line MCF-7 was obtained from the American Type Culture Collection (ATCC, Rockville, MD) and maintained in Dulbecco's Modified Eagle's Medium (Invitrogen, Grand Island, NY) supplemented with 10% feotal bovine serum (FBS) (Invitrogen). Cell lines were incubated under standard conditions in a 37°C humidified 5% CO2 atmosphere.
Reagents and Antibodies
FuGENE 6 transfection reagent was obtained from Roche Applied Science (Indianapolis, IN), pTet-On and ptTS plasmids from Clontech (Palo Alto, CA), dual-luciferase reporter assay system from Promega (Madison, CA), ECL™ western blotting detection reagents from Amersham Biosciences (Little Chalfont, Buckinghamshire, UK), BSA protein assay kit from Pierce (Rockford, IL), and U0126, LY294002, AKT inhibitor IV and PD98059 were purchased from Calbiochem (La Jolla, CA).
Donkey anti-rabbit and anti-mouse IgG peroxidase-labeled antibodies and Cy3-conjugated donkey anti-rabbit IgG were obtained from Amersham Biosciences (Piscataway, NJ), rabbit anti-survivin from Novus Biologicals (Littleton, CO), mouse anti-Bcl-2 from (BD Biosciences), rabbit anti-ERB2 from (Delta Bio labs), rabbit ant-pERB2 was from Upstate (Charlottesville, VA), rabbit anti-Akt and rabbit anti-phospho Ribosomal protein S6 (S235) from Cell Signaling Technology (Danvers, MA), rabbit anti-phoso-Akt S473 from (R&D), and rabbit anti-stat3 C-2 was obtained from Santa Cruz Biotechnology (Santa Cruz, CA).
Inducible expression of HER-2 in the MCF-7 cell line
To produce HER-2 expressing, tetracycline inducible MCF-7 cells, two rounds of stable transfection and selection were used. In the first round, MCF-7 cells were co-transfected with a pTet-On and ptTS at a ratio of 1:10. pTet-ON carries a tetracycline-inducible transcriptional transactivator and ptTS encodes a transcriptional silencer, which binds to the tetracycline response element (TRE) in the absence of tetracycline and decreases background promoter activity. After G418 selection, clones were tested for basal and inducible promoter activity with the tetracycline inducible luciferase reporter plasmid, pTRE-luc (Clontech). The clone that demonstrated the highest ratio of induced/basal activity was then transfected with pTRE-HER2, a construct in which the ErbB2 cDNA was cloned under control of TRE in a pTRE-hygro backbone. After a second round of selection with Hygromycin B, clones were isolated and screened for background and doxycycline-inducible (2 μg/ml) expression of HER-2 by western blotting (described below).
Cells were lysed in buffer (20 mM Tris-HCl pH 8, 100 mM NaCl, 1 mM EDTA, 1% NP-40). Protein concentrations were determined using the BSA protein assay kit. Twenty-five μgs of whole-cell protein lysate from each sample was diluted in 25 μl of SDS loading buffer (4% SDS, 2% glycerol, 0.01% bromphenol blue, 4% β-mercaptoethanol and 125 mM Tris-HCl, pH 6.8), incubated for 5 min at 98°C and 5 min on ice and then centrifuged at 6000 rpm in a microcentrifuge at room temperature. Proteins in the supernatant were resolved on 10% SDS/polyacrylamide gels and transferred to PVDF membranes. Membranes were blocked for 1 h in 5% nonfat dry milk in TBST (10 mM Tris-HCl pH 7.5, 150 mM NaCl and 0.1% Tween 20) and probed for 2 h with primary antibodies diluted in TBST/5% nonfat dry milk as per the supplier's recommendations. Membranes were then washed with TBST 20 minutes × 3 and incubated for 1 h with horseradish peroxidase-labeled secondary antibodies in TBST. After an additional four washes with TBST, bound antibody was visualized by chemiluminescence.
Cloning of survivin promoter in pGL3-Basic vector to produce Survivin-Luciferase
Survivin promoter (nucleotides 1821 – 2800, accession U75285) was amplified by PCR from HeLa genomic DNA using primers:
. The PCR product was first cloned into T-Vector™(Promega) and subsequently sub-cloned into the pGL3-Basic vector to produce Survivin-Luc. Fidelity of PCR cloning was verified by sequencing survivin promoter. MCF-HER2 cells, untreated or induced with doxycycline for 48 hours, were transiently transfected with Survivin-Luc plasmid
Tetracycline-inducible overexpression of HER-2 in MCF7 cell line
Activated HER-2 up-regulates survivin expression in MCF-7 cells
Up regulation of survivin is not due to an increase in G2/M cells in HER 2-overexpressing population
Cell cycle distribution of HER2 transfected MCF-7 cells
MCF7-HER2 (- Dox)
MCF7-HER2 (+ Dox)
Activity of the survivin promoter is not enhanced by HER-2 overexpression in MCF7- cells
Bcl-2 is up-regulated in HER-2 expressing MCF7 cell line
Activation of the ERK signal transduction pathways in response to HER-2 over-expression
NF-kappaB is not activated in response to induction of HER-2 over-expression in MCF7 cells
Up-regulation of survivin in HER-2 induced MCF7 cells is via ERK activation and PI3K signalling
Her-2/neu overexpression is associated with poor overall survival and drug resistance in breast and ovarian cancer patients. Although the molecular mechanisms by which Her-2/neu induces drug resistance are not well established, there is increasing evidence that this resistance is a consequence of deregulation of apoptotic pathways in cells. Chemotherapy, radiation, and immunotherapy all rely heavily on apoptosis to kill breast cancer cells . Therefore we investigated the pro- and anti apoptotic regulators and the signal transduction pathway(s) influenced by tetracycline inducible HER-2 over-expression in MCF-7 breast cancer cell line. The advantage of tetracycline inducible HER-2 expression is that the short-term effect of increased HER-2 expression can be determined. We show that acute over expression of HER-2 in MCF7 cells up-regulates the anti apoptotic protein Bcl-2. Bcl-2 is expressed in 70% of breast cancers and it functions directly in apoptosis regulation and in oncogenesis. Oncogenes such as c-Myc, which drive cells to enter the cell cycle, also engage Bax/Bak-dependent apoptosis . Antiapoptotic Bcl-2 family members can prevent such cell death and thereby promote oncogenic transformation. Additionally high expression level of anti-apoptotic Bcl-2 proteins confers a clinically important chemoresistant phenotype on cancer cells. Likewise, reduced expression of pro-apoptotic Bax levels has been associated with poor response to chemotherapy and shorter overall survival for patients with breast cancers, whereas enhanced expression of Bax protein correlate with a good response to chemotherapy in vivo .
In the absence of new protein synthesis, survivin protein level is expected to decrease steadily with a half-life of approximately 30 minutes . MCF7-HER2 cells, treated with an inhibitor of protein synthesis cycloheximide show a slower decrease in survivin protein level in HER-2 over-expressing MCF7 cells than in control cells (data not shown), which suggests that up-regulation of survivin is post translational. Expression of survivin in tumours correlates with a poor clinical outcome in a variety of malignancies including breast cancer by providing protection against apoptotic stimuli . It is noteworthy that we did not observe a significant anti- apoptotic effect of survivin up regulation after treatment of HER2 over-expressing MCF7 cells with taxol, adriamycin and herceptin (data not shown). This suggests that unlike stable over expression of HER2, an inducible short term HER2 expression and upregulation of survivin is not enough to exert an anti-apoptotic effect.
Growth and survival signals elicited by activated HER-2 are largely mediated via PI3K-Akt and Ras-MAPK signaling pathways. Using specific PI3K, ERK and AKT inhibitors, we show that PI3K and ERK signalling are responsible for up-regulation of survivin in MCF7-Her2 cells. Inhibition of pAKT did not down-regulate survivin in these cells. The exact role of Akt in this process remains to be determined. Down-regulation of survivin may occur independent of p-Akt expression. PI3K-dependent, but Akt-independent, mechanisms by which HER-2 might regulate survivin include effects on serum- and glucocorticoid-induced kinases (SGK), which are serine/threonine kinases that are highly homologous to Akt and, like Akt, are regulated by PI3K. Although the effects of SGK on survivin have not been studied, SGK regulates cell survival  and may therefore be a candidate for regulating survivin protein expression. In addition, PI3K affects cell survival through a protein kinase C-dependent pathway that is mediated by phospholipase Cγ activity . Thus, it is possible that HER-2 regulates survivin in part through PI3K-dependent effects on SGK and/or phospholipase Cγ.
After a short term (48 hours) induction of HER2 in MCF7 breast cancer cells anti-apoptotic proteins survivin and Bcl-2 are up-regulated. PI3K and ERK but not the NF-kappaB, STAT3 and AKT signalling are involved in up-regulation of survivin. Regulation of survivin in HER-2-positive MCF7 cells is not at transcriptional level. Understanding the regulation of HER-2 signalling pathways will help to identify new targets/strategies for the treatment of patients with tumours that are dependent on HER-2 induced signalling pathways for their survival.
This work was supported by the Susan G Komen Breast Cancer Foundation BCTR 0503684 and Cancer Centre Council Grant.
- Fulda S, Debatin KM: Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene. 25 (34): 4798-10.1038/sj.onc.1209608.Google Scholar
- Riedl SJ, Salvesen GS: The apoptosome: signalling platform of cell death. Nat Rev Mol Cell Biol. 2007, 8 (5): 405-10.1038/nrm2153.View ArticlePubMedGoogle Scholar
- Sen S, D'Incalci M: Apoptosis Biochemical events and relevance to cancer chemotherapy. FEBS Letters. 1992, 307 (1): 122-10.1016/0014-5793(92)80914-3.View ArticlePubMedGoogle Scholar
- Alaoui-Jamali MA: The role of ErbB-2 tyrosine kinase receptor in cellular intrinsic chemoresistance: mechanisms and implications. Biochemistry and Cell Biology. 1997, 75 (4): 315-10.1139/bcb-75-4-315.View ArticlePubMedGoogle Scholar
- Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et : Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989, 244 (4905): 707-712. 10.1126/science.2470152.View ArticlePubMedGoogle Scholar
- Klapper LN, Glathe S, Vaisman N, Hynes NE, Andrews GC, Sela M, Yarden Y: The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. PNAS. 1999, 96 (9): 4995-5000. 10.1073/pnas.96.9.4995.View ArticlePubMedPubMed CentralGoogle Scholar
- Guy PM, Platko JV, Cantley LC, Cerione RA, Carraway Kl: Insect Cell-Expressed p180erbB3 Possesses an Impaired Tyrosine Kinase Activity. PNAS. 1994, 91 (17): 8132-8136. 10.1073/pnas.91.17.8132.View ArticlePubMedPubMed CentralGoogle Scholar
- R Pinkas-Kramarski LS, H Waterman, G Levkowitz, I Alroy, L Klapper, S Lavi, R Seger, B J Ratzkin, M Sela, and Y Yarden: Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J. 1996, 15 (10): 2452–2467.-Google Scholar
- Worthylake R, Opresko LK, Wiley HS: ErbB-2 Amplification Inhibits Down-regulation and Induces Constitutive Activation of Both ErbB-2 and Epidermal Growth Factor Receptors. J Biol Chem. 1999, 274 (13): 8865-8874. 10.1074/jbc.274.13.8865.View ArticlePubMedGoogle Scholar
- Ballif BA, Blenis J: Molecular Mechanisms Mediating Mammalian Mitogen-activated Protein Kinase (MAPK) Kinase (MEK)-MAPK Cell Survival Signals. Cell Growth Differ. 2001, 12 (8): 397-408.PubMedGoogle Scholar
- Nagai H, Takuya N, Kohsuke T, Hidenori I: Pathophysiological roles of ASK1-MAP kinase signaling pathways. Journal of Biochemistry and Molecular Biology. 2007, 40 (1): 1-View ArticlePubMedGoogle Scholar
- McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M: Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Advances in Enzyme Regulation. 2006, 46 (1): 249-10.1016/j.advenzreg.2006.01.004.View ArticlePubMedGoogle Scholar
- Fadeel B, Zhivotovsky B, Orrenius S: All along the watchtower: on the regulation of apoptosis regulators. FASEB J. 1999, 13 (13): 1647-1657.PubMedGoogle Scholar
- Reed JC: The Survivin saga goes in vivo. J Clin Invest. 2001, 108 (7): 965-969. 10.1172/JCI14123.View ArticlePubMedPubMed CentralGoogle Scholar
- Danial NN, Korsmeyer SJ: Cell Death: Critical Control Points. Cell. 2004, 116 (2): 205-10.1016/S0092-8674(04)00046-7.View ArticlePubMedGoogle Scholar
- Cheng EHYA, Wei MC, Weiler S, Flavell RA, Mak TW, Lindsten T, Korsmeyer SJ: BCL-2, BCL-XL Sequester BH3 Domain-Only Molecules Preventing BAX- and BAK-Mediated Mitochondrial Apoptosis. Molecular Cell. 2001, 8 (3): 705-10.1016/S1097-2765(01)00320-3.View ArticlePubMedGoogle Scholar
- Wei MC, Zong WX, Cheng EHY, Lindsten T, Panoutsakopoulou V, Ross AJ, Roth KA, MacGregor GR, Thompson CB, Korsmeyer SJ: Proapoptotic BAX and BAK: A Requisite Gateway to Mitochondrial Dysfunction and Death. Science. 2001, 292 (5517): 727-730. 10.1126/science.1059108.View ArticlePubMedPubMed CentralGoogle Scholar
- Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 1998, 396 (6711): 580-10.1038/25141.View ArticlePubMedGoogle Scholar
- Dohi T, Beltrami E, Wall NR, Plescia J, Altieri DC: Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest. 2004, 114 (8): 1117-1127.View ArticlePubMedPubMed CentralGoogle Scholar
- Kumar R, Mandal M, Lipton A, Harvey H, Thompson CB: Overexpression of HER2 modulates bcl-2, bcl-XL, and tamoxifen-induced apoptosis in human MCF-7 breast cancer cells. Clin Cancer Res. 1996, 2 (7): 1215-1219.PubMedGoogle Scholar
- Xia W, Bisi J, Strum J, Liu L, Carrick K, Graham KM, Treece AL, Hardwicke MA, Dush M, Liao Q, Westlund RE, Zhao S, Bacus S, Spector NL: Regulation of Survivin by ErbB2 Signaling: Therapeutic Implications for ErbB2-Overexpressing Breast Cancers. Cancer Res. 2006, 66 (3): 1640-1647. 10.1158/0008-5472.CAN-05-2000.View ArticlePubMedGoogle Scholar
- Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M: Transcriptional Repression of the Anti-apoptotic survivin Gene by Wild Type p53. J Biol Chem. 2002, 277 (5): 3247-3257. 10.1074/jbc.M106643200.View ArticlePubMedGoogle Scholar
- Zhao J, Tenev T, Martins LM, Downward J, Lemoine NR: The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. J Cell Sci. 2000, 113 (23): 4363-4371.PubMedGoogle Scholar
- Marmor MD, Skaria KB, Yarden Y: Signal transduction and oncogenesis by ErbB/HER receptors. International Journal of Radiation Oncology*Biology*Physics. 2004, 58 (3): 903-10.1016/j.ijrobp.2003.06.002.View ArticleGoogle Scholar
- Ly C, Arechiga AF, Melo JV, Walsh CM, Ong ST: Bcr-Abl Kinase Modulates the Translation Regulators Ribosomal Protein S6 and 4E-BP1 in Chronic Myelogenous Leukemia Cells via the Mammalian Target of Rapamycin. Cancer Res. 2003, 63 (18): 5716-5722.PubMedGoogle Scholar
- Debatin KM: Activation of apoptosis pathways by anticancer treatment. Toxicology Letters. 2000, 112-113: 41-10.1016/S0378-4274(99)00252-0.View ArticlePubMedGoogle Scholar
- Juin P, Hunt A, Littlewood T, Griffiths B, Swigart LB, Korsmeyer S, Evan G: c-Myc Functionally Cooperates with Bax To Induce Apoptosis. Mol Cell Biol. 2002, 22 (17): 6158-6169. 10.1128/MCB.22.17.6158-6169.2002.View ArticlePubMedPubMed CentralGoogle Scholar
- Shore GC, Viallet J: Modulating the Bcl-2 Family of Apoptosis Suppressors for Potential Therapeutic Benefit in Cancer. Hematology. 2005, 2005 (1): 226-230. 10.1182/asheducation-2005.1.226.View ArticleGoogle Scholar
- Krajewski S, Krajewska M, Turner BC, Pratt C, Howard B, Zapata JM, Frenkel V, Robertson S, Ionov Y, Yamamoto H, Perucho M, Takayama S, Reed JC: Prognostic significance of apoptosis regulators in breast cancer. Endocr Relat Cancer. 1999, 6 (1): 29-40. 10.1677/erc.0.0060029.View ArticlePubMedGoogle Scholar
- Ambrosini G: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nature Medicine. 1997, 3 (8): 917-10.1038/nm0897-917.View ArticlePubMedGoogle Scholar
- Brunet A, Park J, Tran H, Hu LS, Hemmings BA, Greenberg ME: Protein Kinase SGK Mediates Survival Signals by Phosphorylating the Forkhead Transcription Factor FKHRL1 (FOXO3a). Mol Cell Biol. 2001, 21 (3): 952-965. 10.1128/MCB.21.3.952-965.2001.View ArticlePubMedPubMed CentralGoogle Scholar
- Fang X, Yu S, Tanyi JL, Lu Y, Woodgett JR, Mills GB: Convergence of Multiple Signaling Cascades at Glycogen Synthase Kinase 3: Edg Receptor-Mediated Phosphorylation and Inactivation by Lysophosphatidic Acid through a Protein Kinase C-Dependent Intracellular Pathway. Mol Cell Biol. 2002, 22 (7): 2099-2110. 10.1128/MCB.22.7.2099-2110.2002.View ArticlePubMedPubMed CentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/8/129/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.